Israel - Hebräisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

Israel - Hebräisch - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - טבליות מצופות פילם - lamivudine 150 mg - lamivudine - lamivudine - epivir (lamivudine) is indicated for use in combination with retrovir (zidovudine) for the treatment of human immunodeficiency virus (hiv) infection when antiretroviral therapy is warranted based on clinical and/or immunological evidence of disease progression.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - תמיסה (פומי) - lamivudine 5 mg/ml - lamivudine - lamivudine - zeffix is indicated for the treatment of chronic hepatitis b associated with the evidence of hepatitis b viral (hbv) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - תמיסה (פומי) - lamivudine 10 mg/ml - lamivudine - lamivudine - epivir (lamivudine) is indicated for use in combination with retrovir (zidovudine) for the treatment of human immunodeficiency virus (hiv) infection when antiretroviral therapy is warranted based on clinical and/or immunological evidence of disease progression.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - טבליות מצופות פילם - lamivudine 300 mg - lamivudine - lamivudine - epivir (lamivudine) is indicated for use in combination with retrovir (zidovudine) for the treatment of human immunodeficiency virus (hiv) infection when antiretroviral therapy is warranted based on clinical and/or immunological evidence of disease progression.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate - תמיסה (פומי) - abacavir as sulfate 20 mg/ml - abacavir - abacavir - ziagen is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.

Israel - Hebräisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - אבקה להכנת תמיסה להחדרה - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 120 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 400 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.